At the end of October, we attended the inaugural Neuromuscular Drug Development Summit. This new meeting brought together thought leaders from industry, academia, and the patient advocacy community to discuss scientific progress and issues affecting companies developing drugs for these mostly rare diseases. Neuromuscular diseases — such as muscular dystrophies, motor neuron diseases, mitochondrial...